相关实验视频

Updated: May 9, 2025

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

结核病疫苗开发中的目标和策略

Bidyarani Devi Konjengbam¹, Heikrujam Nilkanta Meitei¹, Anupama Pandey¹

¹Department of Biotechnology, Manipur University, Canchipur, Imphal, Manipur 795003, India.

Molecular immunology

|May 6, 2025

概括

由于耐药性和BCG疗效下降,开发新的结核病 (TB) 疫苗至关重要. 本综述探讨了结核病预防的创新疫苗策略,挑战和未来前景.

科学领域:

免疫学免疫学免疫学
疫苗学疫苗学疫苗学
传染性疾病传染性疾病

背景情况:

由Mycobacterium tuberculosis引起的结核病 (TB) 仍然是一个全球卫生挑战,由多抗药性 (MDR-TB) 和广泛抗药性 (XDR-TB) 菌株加剧.
目前的Bacille Calmette-Guerin (BCG) 疫苗在成年人中提供有限的保护,而抗结核病药物治疗有显著的副作用和长时间.
疫苗接种是克服当前结核病控制方法局限性的最有前途的策略.

研究的目的:

审查结核病疫苗开发中的多种方法,突出挑战和进展.
讨论临床前和临床试验的障碍,以及像DNA疫苗这样的新策略.
探索免疫信息学和基于纳米材料的输送系统在提高结核病疫苗疗效方面的潜力.

主要方法:

结核病疫苗研究的综合文献综述,包括传统和新的方法.
分析临床前和临床开发中的挑战,包括疗效和安全性评估.
探索新兴技术,如DNA疫苗,免疫信息学和用于疫苗的纳米技术.

主要成果:

该审查综合了有关各种结核病疫苗候选人和开发策略的信息.
确定结核病疫苗开发的重大挑战,包括需要提高有效性,安全性和保护持续时间.
突出了先进方法的潜力,如DNA疫苗和基于纳米材料的输送系统.

结论:

疫苗接种仍然是有效控制结核病的最可行的策略,为耐药性和BCG限制提供了潜在的解决方案.
对新型疫苗平台的进一步研究,包括DNA疫苗和以免疫信息学为指导的开发,是必不可少的.
基于纳米材料的输送系统显示出提高疫苗免疫性和疗效的前景,为未来的结核病预防铺平了道路.

关键词:

在BCG中,BCG是BCG.促进BCG的增强主体导向疗法主体导向疗法免疫信息学是一种免疫信息学.纳米材料的使用方法疫苗的犹疫苗的犹

更多相关视频

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

相关概念视频

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...